What The New US Cholesterol Treatment Guidelines Mean For Esperion

Guidelines place high emphasis on low cost, but also outcomes data. Esperion plans to file bempedioc acid next year, but outcomes data won’t be available until 2022.

3d rendering Human Heart

Esperion Therapeutics Inc. foresees a boost for its oral bempedoic acid from the latest round of US cholesterol treatment guidelines, which promote the use of add-on therapies for further LDL-lowering on top of statins and emphasize cost-effectiveness.

Esperion plans to file bempedoic acid, an oral ATP citrate lyase inhibitor, for approval as a monotherapy and in a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category